Scilex Holding Company (SCLX)
NASDAQ: SCLX · IEX Real-Time Price · USD
1.080
-0.030 (-2.70%)
At close: May 31, 2024, 4:00 PM
1.150
+0.070 (6.48%)
After-hours: May 31, 2024, 6:50 PM EDT
Scilex Holding Company Revenue
Scilex Holding Company had revenue of $47.05M in the twelve months ending March 31, 2024, with 12.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $10.88M with 2.85% year-over-year growth. In the year 2023, Scilex Holding Company had annual revenue of $46.74M with 22.90% growth.
Revenue (ttm)
$47.05M
Revenue Growth
+12.54%
P/S Ratio
4.16
Revenue / Employee
$443,821
Employees
106
Market Cap
195.69M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.74M | 8.71M | 22.90% |
Dec 31, 2022 | 38.03M | 6.72M | 21.45% |
Dec 31, 2021 | 31.32M | 7.76M | 32.92% |
Dec 31, 2020 | 23.56M | 2.53M | 12.01% |
Dec 31, 2019 | 21.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inogen | 321.52M |
NeuroPace | 69.07M |
Semler Scientific | 65.88M |
Zevra Therapeutics | 28.01M |
TriSalus Life Sciences | 21.98M |
Delcath Systems | 4.61M |
SCLX News
- 3 days ago - Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company - GlobeNewsWire
- 9 days ago - Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - GlobeNewsWire
- 9 days ago - Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - GlobeNewsWire
- 19 days ago - Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba® - GlobeNewsWire
- 20 days ago - Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces $15 Million Registered Direct Offering - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses - GlobeNewsWire